Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

First, the liver cancer treatment 'TULBEGIO ... a boom in biosimilars is expected, so this year, even more domestically produced new drugs and pharmaceuticals are expected to receive FDA approval ...

Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...

Johnson & Johnson surpasses expectations with robust fourth-quarter profits, backed by its acquisition of Intra-Cellular and ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

The cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...